Immuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program
May 07, 2018 21:43 ET
|
Immuron Limited
MELBOURNE, Australia, May 07, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally...
UPDATE -- Immuron Commences US Non-Deal Institutional Investor Roadshow
March 13, 2018 02:15 ET
|
Immuron Limited
MELBOURNE, Australia, March 13, 2018 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC)(NASDQ:IMRN) is pleased to release to shareholders and investors its...
Immuron Commences US Non-Deal Institutional Investor Roadshow
March 12, 2018 08:17 ET
|
Immuron Limited
MELBOURNE, Australia, March 12, 2018 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC)(NASDQ:IMRN) is pleased to release to shareholders and investors its...
Immuron Limited Issues Correction to Misleading Halt Announcement Headline
March 07, 2018 17:06 ET
|
Immuron Limited
MELBOURNE, Australia, March 07, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) wishes to correct a misleading halt announcement released over the wire yesterday. ...
Travelan® Revenue Grows Significantly in US and Australia
February 16, 2018 09:30 ET
|
Immuron Limited
Key Highlights: Immuron’s flagship product Travelan® reports revenue in excess of AUS$914K for first 6mths of FY2018 Travelan® US experienced a 250% increase in sales year over year reaching...
Immuron Enrols First Patients in Clinical Study of IMM-529 for Treatment of Clostridium Difficile Infection (CDI)
January 31, 2018 09:30 ET
|
Immuron Limited
Key Highlights: First patients enrolled in Immuron’s IMM-529 clinical study at Hadassah Medical Center in Israel Trial will treat 60 confirmed patients over 28 days to evaluate safety and efficacy of...
US Defense Reports Broad Travelan® Reactivity to 180 Pathogenic Bacteria Including Camylobacter and Shigella
January 29, 2018 09:20 ET
|
Immuron Limited
Key Highlights: The research program was performed by the U.S. Department of Defense (DoD) and was conducted by the Department of Enteric Diseases, Armed Forces Research Institute of Medical Sciences...
CEO to Present on US Investor TV Show and at Biotech Conference
January 10, 2018 09:00 ET
|
Immuron Limited
MELBOURNE, Australia, Jan. 10, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to advise investors that CEO Dr Jerry Kanellos, was interviewed on The...
Immuron to Present at RedChip’s Global Online Growth Conference
December 06, 2017 09:04 ET
|
Immuron Limited
MELBOURNE, Australia, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) wishes to advise investors that CEO Dr Jerry Kanellos is scheduled to present at...
Van Leeuwenhoeck Institute Updates Immuron Research Coverage
November 22, 2017 09:00 ET
|
Immuron Limited
MELBOURNE, Australia, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (the “Company”) wishes to advise investors that Van Leeuwenhoeck Institute, a prominent European and US-based Life...